AU2008266807B2 - Promoterless cassettes for expression of alphavirus structural proteins - Google Patents

Promoterless cassettes for expression of alphavirus structural proteins Download PDF

Info

Publication number
AU2008266807B2
AU2008266807B2 AU2008266807A AU2008266807A AU2008266807B2 AU 2008266807 B2 AU2008266807 B2 AU 2008266807B2 AU 2008266807 A AU2008266807 A AU 2008266807A AU 2008266807 A AU2008266807 A AU 2008266807A AU 2008266807 B2 AU2008266807 B2 AU 2008266807B2
Authority
AU
Australia
Prior art keywords
alphavirus
rna
helper
rna molecule
replicon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008266807A
Other languages
English (en)
Other versions
AU2008266807A1 (en
Inventor
Kurt I. Kamrud
Maureen Maughan
Jonathan F. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphavax Inc
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Publication of AU2008266807A1 publication Critical patent/AU2008266807A1/en
Application granted granted Critical
Publication of AU2008266807B2 publication Critical patent/AU2008266807B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008266807A 2007-06-21 2008-06-20 Promoterless cassettes for expression of alphavirus structural proteins Active AU2008266807B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93663707P 2007-06-21 2007-06-21
US60/936,637 2007-06-21
PCT/US2008/007701 WO2008156829A2 (en) 2007-06-21 2008-06-20 Promoterless cassettes for expression of alphavirus structural proteins

Publications (2)

Publication Number Publication Date
AU2008266807A1 AU2008266807A1 (en) 2008-12-24
AU2008266807B2 true AU2008266807B2 (en) 2012-08-16

Family

ID=40156867

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008266807A Active AU2008266807B2 (en) 2007-06-21 2008-06-20 Promoterless cassettes for expression of alphavirus structural proteins

Country Status (13)

Country Link
US (2) US7850977B2 (enExample)
EP (2) EP2947149B1 (enExample)
JP (3) JP5602624B2 (enExample)
CN (1) CN101802199B (enExample)
AU (1) AU2008266807B2 (enExample)
CA (1) CA2689588C (enExample)
DK (2) DK2947149T3 (enExample)
ES (2) ES2588906T3 (enExample)
IL (1) IL202720A (enExample)
NZ (1) NZ582495A (enExample)
PL (2) PL2947149T3 (enExample)
WO (1) WO2008156829A2 (enExample)
ZA (1) ZA200909080B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582495A (en) * 2007-06-21 2012-05-25 Alphavax Inc Promoterless cassettes for expression of alphavirus structural proteins
WO2010065414A1 (en) 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
ES2540958T3 (es) 2009-04-08 2015-07-15 Alphavax, Inc. Partículas de replicón de alfavirus que expresan TRP2
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
BE1023557B1 (fr) 2014-02-10 2017-05-03 Univercells Sa Systeme, appareil et procede pour la production de biomolecules
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
WO2017123652A1 (en) 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
US10538786B2 (en) 2016-04-13 2020-01-21 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
EP3526332B1 (en) 2016-10-17 2024-06-26 Janssen Pharmaceuticals, Inc. Recombinant virus replicon systems and uses thereof
CA3045650A1 (en) * 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
EP3681993A1 (en) * 2017-09-13 2020-07-22 BioNTech RNA Pharmaceuticals GmbH Rna replicon for reprogramming somatic cells
AU2018333530B2 (en) * 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
JP7731670B2 (ja) 2017-11-06 2025-09-01 インターベット インターナショナル ベー． フェー． ネコ白血病ウイルスワクチン
US11167027B2 (en) 2017-11-06 2021-11-09 Intervet Inc. Multivalent feline vaccine
BR112020008958A2 (pt) 2017-11-06 2021-05-11 Intervet International B.V. vacina contra calicivírus felino
WO2019110213A1 (en) 2017-12-08 2019-06-13 Intervet International B.V. Feline calicivirus vaccine
WO2019115090A1 (en) 2017-12-15 2019-06-20 Intervet International B.V. Multivalent feline vaccine
JP7472019B2 (ja) 2017-11-06 2024-04-22 インターベット インターナショナル ベー． フェー． 狂犬病ウイルスワクチン
JP7825939B2 (ja) 2017-12-04 2026-03-09 インターベット インターナショナル ベー． フェー． イヌライム病ワクチン
EP3720488A1 (en) 2017-12-04 2020-10-14 Intervet International B.V. Vaccination with replicon particles and oil adjuvant
JP7346417B2 (ja) 2017-12-18 2023-09-19 インターベット インターナショナル ベー． フェー． ブタインフルエンザａウイルスワクチン
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
WO2019124441A1 (en) 2017-12-20 2019-06-27 Vlp Therapeutics, Llc Alphavirus replicon particle
BR112020014525A2 (pt) 2018-01-19 2020-12-08 Janssen Pharmaceuticals, Inc. Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
US12331076B2 (en) 2018-10-08 2025-06-17 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
CN113194989B (zh) 2018-12-20 2024-01-30 英特维特国际股份有限公司 初免-强化免疫接种方案
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
EP4135847A4 (en) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus vaccine
CA3174651A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
WO2021228731A1 (en) 2020-05-11 2021-11-18 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
JP2023530135A (ja) 2020-06-19 2023-07-13 インターベット インターナショナル ベー． フェー． 特定のウイルス系統の抗原をエンコードする核酸構築物を含むブタインフルエンザａウイルスワクチン
BR112022024932A2 (pt) * 2020-06-19 2022-12-27 Intervet Int Bv Vacina contra vírus da influenza a suína compreendendo um constructo de ácido nucleico que possui uma ordem específica de genes
WO2021255225A1 (en) 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
US20230277649A1 (en) 2020-06-19 2023-09-07 Intervet Inc. Swine influenza a virus vaccine comprising two distinct rna replicon particles
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
WO2022049276A1 (en) 2020-09-07 2022-03-10 Intervet International B.V. Ha stem vaccine for ha antibody-positive targets
JP2023549787A (ja) 2020-11-12 2023-11-29 インターベット インターナショナル ベー． フェー． キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
US20250281597A1 (en) 2021-10-25 2025-09-11 Intervet Inc. A vaccine for the protection of piglets against swine influenza a virus infection
EP4696782A1 (en) 2024-08-14 2026-02-18 Starvax One B.V. Improved split rna replicons
WO2026037537A1 (en) 2024-08-16 2026-02-19 Intervet International B.V. Canine influenza virus vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177819A1 (en) * 2001-09-06 2006-08-10 Alphavax, Inc. Alphavirus replicon vector systems

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US6770283B1 (en) 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US20020102273A1 (en) 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
RU2057377C1 (ru) 1993-08-23 1996-03-27 Уральский электрохимический комбинат Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6197879B1 (en) * 1995-10-31 2001-03-06 Henkel Corporation Methods of preparing inorganic pigment dispersions
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
WO1997040165A1 (en) 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CZ438398A3 (cs) 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
JP2965908B2 (ja) 1996-07-05 1999-10-18 株式会社精工技研 調温液体シール手段を備える光ディスク成形用金型装置
US5827658A (en) 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
FR2757169B1 (fr) 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB9716611D0 (en) 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
FI106618B (fi) 1998-03-30 2001-03-15 Sandvik Tamrock Oy Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
AU754320B2 (en) 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer
EP1080218A1 (en) 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
CA2336554A1 (en) 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
US7267823B2 (en) 1998-06-29 2007-09-11 United States Of America As Represented By The Secretary Of The Army Ebola peptides and immunogenic compositions containing same
EP1119626B1 (en) 1998-07-10 2008-01-02 U.S. Army Medical Research Institute of Infectious Diseases Botulinum neurotoxin vaccine
US6770479B1 (en) 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
DE69941454D1 (de) 1998-07-10 2009-11-05 U S Medical Res Inst Of Infect Impfstoff gegen staphylokokken-vergiftung
AU6289699A (en) 1998-10-05 2000-04-26 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
ATE465266T1 (de) 1998-12-31 2010-05-15 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000061772A2 (en) 1999-04-14 2000-10-19 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DE60040672D1 (de) 1999-08-31 2008-12-11 Univ North Carolina Antikörper-abhängige vergrösserung der alphavirus-infektvität
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
JP2003511037A (ja) * 1999-10-01 2003-03-25 ジェノボ， インコーポレイテッド ＡＡＶｒｅｐ／ｃａｐ遺伝子を含むアデノウイルスを使用する組換えＡＡＶの産生
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
WO2002003917A2 (en) 2000-07-07 2002-01-17 Alphavax, Inc. Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
EP1305518B1 (en) 2000-07-28 2004-06-16 Visteon Global Technologies, Inc. An air intake arrangement for an internal combustion engine
BR0113577A (pt) 2000-08-29 2004-07-06 Wyeth Corp Empacotamento de partìculas de replicon de vìrus de rna de filamento positivo
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
DE10049587A1 (de) 2000-10-06 2002-05-02 Icon Genetics Ag Vektorsystem für Pflanzen
DE10061150A1 (de) 2000-12-08 2002-06-13 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
US6800289B2 (en) 2000-12-21 2004-10-05 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Strain of the western equine encephalitis virus
ATE499948T1 (de) 2001-01-12 2011-03-15 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
JP4608210B2 (ja) 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
DE10143238A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente
WO2003083065A2 (en) 2002-03-25 2003-10-09 University Of North Carolina At Chapel Hill Improved methods for achieving expression from alphavirus vectors
JP3857195B2 (ja) 2002-07-09 2006-12-13 株式会社東芝 距離継電装置
EP1583500A4 (en) 2002-11-13 2008-02-13 Us Navy METHOD AND COMPOSITIONS FOR INDUCTION OF IMMUNE REACTIONS AND PROTECTION IMMUNITY BY PRIMING WITH ALPHAVIRUS REPLICONIC VACCINES
ES2630222T3 (es) 2002-12-13 2017-08-18 Alphavax, Inc. Partículas alfavíricas y métodos de preparación
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
CN1791678A (zh) 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
US20060099587A1 (en) 2003-06-20 2006-05-11 Johnston Robert E Alphavirus vectors having attentuated virion structural proteins
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US20050208020A1 (en) 2003-11-12 2005-09-22 Doolan Denise L Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
US7078087B2 (en) * 2003-12-31 2006-07-18 Kimberly-Clark Worldwide, Inc. Wipes with an edge treatment along a leading edge portion
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
US7862829B2 (en) * 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
EP1856250B1 (en) 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill New live virus vaccines
WO2008033966A2 (en) 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
NZ582495A (en) * 2007-06-21 2012-05-25 Alphavax Inc Promoterless cassettes for expression of alphavirus structural proteins
JP5758632B2 (ja) * 2008-01-24 2015-08-05 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177819A1 (en) * 2001-09-06 2006-08-10 Alphavax, Inc. Alphavirus replicon vector systems

Also Published As

Publication number Publication date
DK2183368T3 (en) 2016-09-05
ZA200909080B (en) 2010-09-29
PL2183368T3 (pl) 2016-12-30
JP2010530245A (ja) 2010-09-09
HK1217216A1 (en) 2016-12-30
EP2947149B1 (en) 2018-02-28
EP2183368A4 (en) 2011-04-13
JP2016198114A (ja) 2016-12-01
US20100183665A1 (en) 2010-07-22
EP2183368A2 (en) 2010-05-12
JP5995926B2 (ja) 2016-09-21
CA2689588A1 (en) 2008-12-24
US8460913B2 (en) 2013-06-11
JP5602624B2 (ja) 2014-10-08
PL2947149T3 (pl) 2018-09-28
AU2008266807A1 (en) 2008-12-24
IL202720A0 (en) 2011-08-01
JP2014230544A (ja) 2014-12-11
WO2008156829A2 (en) 2008-12-24
CN101802199B (zh) 2012-08-22
EP2183368B1 (en) 2016-08-10
NZ582495A (en) 2012-05-25
ES2588906T3 (es) 2016-11-07
ES2670813T3 (es) 2018-06-01
CN101802199A (zh) 2010-08-11
US7850977B2 (en) 2010-12-14
IL202720A (en) 2013-10-31
CA2689588C (en) 2016-08-23
DK2947149T3 (en) 2018-06-06
WO2008156829A3 (en) 2009-03-12
EP2947149A1 (en) 2015-11-25
US20090075384A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
AU2008266807B2 (en) Promoterless cassettes for expression of alphavirus structural proteins
US10570416B2 (en) TC-83-derived alphavirus vectors, particles and methods
KR101518309B1 (ko) 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US8961995B2 (en) Methods and compositions for alphavirus replicons
HK1217216B (en) Alphavirus replicon particles for use in vaccination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)